All In Biotech

Drug Trial Radar · NCT02577926

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

207

Actual

Start

Oct 2015

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
RWTH Aachen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis Pharmaceuticals
First posted
Oct 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow fibrosis, and disease-related symptoms including pruritus, night sweats, fever, weight loss, cachexia, and diarrhea. In addition, due to elevated numbers of leucocytes, erythrocytes and/or platelets, the disease course can be complicated by thromboembolic disease, hemorrhage, and leukemic transformation as well as myelofibrosis. Patients with polycythemia vera (PV) typically harbor an increased number of blood cells from all three hematopoietic cell lineages due to clonal amplification of hematopoetic stem cells, while patients with essential thrombocythemia (ET) typically show a predominant expansion of the megakaryocytic lineage. Most patients with PV below the age of 60 years are currently being treated with acetylsalicylic acid +/- phlebotomy only, and patients with low-risk ET have an almost normal life expectancy and often do not require specific treatment. However, PV- as well as ET-patients with a higher risk for complications require cytoreductive treatment. In addition, constitutional symptoms can be unbearable to patients even in the absence of bona fide high risk factors, and these patients may similarly benefit from antineoplastic therapy.

Conditions

  • Polycythemia Vera (PV)
  • Essential Thrombocythemia (ET)

Interventions

  • RuxolitinibDrug

    Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.

  • BATDrug

    BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al 2009Time frame: at month 6

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Charite Universitätsmedizin Berlin; Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie

    Berlin, Germany

  • Universitätsklinikum Freiburg - Klinik für Innere Medizin I

    Freiburg im Breisgau, Germany

  • Universitätsklinik Jena - Klinik für Innere Medizin II

    Jena, Germany

  • UNIVERSITÄTSKLINIKUM Schleswig-Holstein - Klinik für Hämatologie und Onkologie, Campus Lübeck

    Lübeck, Germany

  • Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie

    Mannheim, Baden-Wurttemberg, Germany

  • Universitätsklinikum Ulm Klinik für Innere Medizin III

    Ulm, Baden-Wurttemberg, Germany

  • Rems-Murr Klinikum Winnenden

    Winnenden, Baden-Wurttemberg, Germany

  • Studienzentrum Aschaffenburg

    Aschaffenburg, Bavaria, Germany

  • III. Medizinischen Klinik des Klinikums rechts der Isar der TU München

    Müchen, Bavaria, Germany

  • Klinikum Nürnberg Nord Medizinische Klinik 5

    Nuremberg, Bavaria, Germany

  • Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik

    Mainz, Hesse, Germany

  • Uniklinik RWTH Aachen

    Aachen, North Rhine-Westphalia, Germany

  • Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III

    Bonn, North Rhine-Westphalia, Germany

  • Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik

    Duisburg, North Rhine-Westphalia, Germany

  • Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie

    Düsseldorf, North Rhine-Westphalia, Germany

  • Marienhospital

    Düsseldorf, North Rhine-Westphalia, Germany

  • Universitätsklinikum Essen Klinik für Hämatologie

    Essen, North Rhine-Westphalia, Germany

  • Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin

    Minden, North Rhine-Westphalia, Germany

  • Universitätsklinikum Magdeburg

    Magdeburg, Sachesen-Anhalt, Germany

  • Klinikum Chemnitz gGmbH Klinik für Innere Medizin III

    Chemnitz, Saxony, Germany

  • Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I

    Dresden, Saxony, Germany

  • Universitätsklinikum Halle (Saale)

    Halle, Saxony-Anhalt, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.